130 related articles for article (PubMed ID: 32322178)
1. Impact of bone events on survival in solitary bone plasmacytoma.
Mauro GP; Neffá PP; Villar RC; Martinez GA; Carvalho HA
Rep Pract Oncol Radiother; 2020; 25(3):389-395. PubMed ID: 32322178
[TBL] [Abstract][Full Text] [Related]
2. Reossification and prognosis following radiotherapy with/without surgery for spinal solitary plasmacytoma of the bone: a retrospective study of 39 patients.
Ouyang H; Han S; Jiang L; Zhuang H; Yang S; Liu Y; Zhang L; Liu X; Wei F; Chen K; Zhou S; Liu Z
Spine J; 2020 Feb; 20(2):283-291. PubMed ID: 31546017
[TBL] [Abstract][Full Text] [Related]
3. Radiotherapy Alone is Associated with Improved Outcomes Over Surgery in the Management of Solitary Plasmacytoma.
Li QW; Niu SQ; Wang HY; Wen G; Li YY; Xia YF; Zhang YJ
Asian Pac J Cancer Prev; 2015; 16(9):3741-5. PubMed ID: 25987031
[TBL] [Abstract][Full Text] [Related]
4. Clinical features and prognostic factors in solitary plasmacytoma.
Finsinger P; Grammatico S; Chisini M; Piciocchi A; Foà R; Petrucci MT
Br J Haematol; 2016 Feb; 172(4):554-60. PubMed ID: 26684545
[TBL] [Abstract][Full Text] [Related]
5. Safety and Feasibility Analysis of a Prospective Trial on Stereotactic Body Radiotherapy for Solitary Bone Plasmacytoma.
Mauro GP; Neffá PP; Villar RC; Martinez GA; de Andrade Carvalho H
Acta Haematol; 2021; 144(6):627-632. PubMed ID: 34247172
[TBL] [Abstract][Full Text] [Related]
6. Radiotherapy in the treatment of solitary plasmacytoma.
Jyothirmayi R; Gangadharan VP; Nair MK; Rajan B
Br J Radiol; 1997 May; 70(833):511-6. PubMed ID: 9227234
[TBL] [Abstract][Full Text] [Related]
7. Pattern of care and impact of prognostic factors on the outcome of head and neck extramedullary plasmacytoma: a systematic review and individual patient data analysis of 315 cases.
Venkatesulu B; Mallick S; Giridhar P; Upadhyay AD; Rath GK
Eur Arch Otorhinolaryngol; 2018 Feb; 275(2):595-606. PubMed ID: 29224044
[TBL] [Abstract][Full Text] [Related]
8. Persistence of myeloma protein for more than one year after radiotherapy is an adverse prognostic factor in solitary plasmacytoma of bone.
Wilder RB; Ha CS; Cox JD; Weber D; Delasalle K; Alexanian R
Cancer; 2002 Mar; 94(5):1532-7. PubMed ID: 11920511
[TBL] [Abstract][Full Text] [Related]
9. Long-term Outcomes After Definitive Radiation Therapy for Solitary Plasmacytoma.
Curry J; O'steen L; Morris CG; Kirwan JM; Mendenhall WM
Am J Clin Oncol; 2020 Oct; 43(10):709-713. PubMed ID: 32739971
[TBL] [Abstract][Full Text] [Related]
10. Radiotherapy for solitary plasmacytoma of bone and soft tissue: outcomes and prognostic factors.
Suh YG; Suh CO; Kim JS; Kim SJ; Pyun HO; Cho J
Ann Hematol; 2012 Nov; 91(11):1785-93. PubMed ID: 22752147
[TBL] [Abstract][Full Text] [Related]
11. Radiotherapy for the treatment of solitary plasmacytoma: 7-year outcomes by a mono-institutional experience.
Alghisi A; Borghetti P; Maddalo M; Roccaro AM; Tucci A; Mazzola R; Magrini SM; Lo Casto A; Bonù ML; Tomasini D; Pasinetti N; Peretto G; Bertagna F; Tomasi C; Buglione M; Triggiani L
J Cancer Res Clin Oncol; 2021 Jun; 147(6):1773-1779. PubMed ID: 33201300
[TBL] [Abstract][Full Text] [Related]
12. Solitary plasmacytoma treated with radiotherapy: impact of tumor size on outcome.
Tsang RW; Gospodarowicz MK; Pintilie M; Bezjak A; Wells W; Hodgson DC; Stewart AK
Int J Radiat Oncol Biol Phys; 2001 May; 50(1):113-20. PubMed ID: 11316553
[TBL] [Abstract][Full Text] [Related]
13. Long-term outcome of patients with solitary plasmacytoma treated with radiotherapy: A population-based, single-center study with median follow-up of 13.7 years.
Barzenje DA; Kolstad A; Ghanima W; Holte H
Hematol Oncol; 2018 Feb; 36(1):217-223. PubMed ID: 28393375
[TBL] [Abstract][Full Text] [Related]
14. Clinical features, outcome, and prognostic factors for survival and evolution to multiple myeloma of solitary plasmacytomas: a report of the Greek myeloma study group in 97 patients.
Katodritou E; Terpos E; Symeonidis AS; Pouli A; Kelaidi C; Kyrtsonis MC; Kotsopoulou M; Delimpasi S; Christoforidou A; Giannakoulas N; Viniou NA; Stefanoudaki E; Hadjiaggelidou C; Christoulas D; Verrou E; Gastari V; Papadaki S; Polychronidou G; Papadopoulou A; Giannopoulou E; Kastritis E; Kouraklis A; Konstantinidou P; Anagnostopoulos A; Zervas K; Dimopoulos MA
Am J Hematol; 2014 Aug; 89(8):803-8. PubMed ID: 24757085
[TBL] [Abstract][Full Text] [Related]
15. Solitary plasmacytoma.
Dagan R; Morris CG; Kirwan J; Mendenhall WM
Am J Clin Oncol; 2009 Dec; 32(6):612-7. PubMed ID: 19593082
[TBL] [Abstract][Full Text] [Related]
16. Solitary plasmacytoma of bone and soft tissue.
Bolek TW; Marcus RB; Mendenhall NP
Int J Radiat Oncol Biol Phys; 1996 Sep; 36(2):329-33. PubMed ID: 8892456
[TBL] [Abstract][Full Text] [Related]
17. Solitary Plasmacytoma of Bone of the Spine: Results From Surveillance, Epidemiology, and End Results (SEER) Registry.
Wang Y; Li H; Liu C; Chen C; Yan J
Spine (Phila Pa 1976); 2019 Jan; 44(2):E117-E125. PubMed ID: 30005040
[TBL] [Abstract][Full Text] [Related]
18. Clinical presentation and outcomes of solitary plasmacytoma in a tertiary hospital in the UK.
Agbuduwe C; Yang H; Gaglani J; Ajithkumar T
Clin Med (Lond); 2020 Sep; 20(5):e191-e195. PubMed ID: 32934063
[TBL] [Abstract][Full Text] [Related]
19. Maximizing the Clinical Benefit of Radiotherapy in Solitary Plasmacytoma: An International Multicenter Analysis.
Elsayad K; Oertel M; König L; Hüske S; Le Ray E; Meheissen MAM; Elsaid AA; Elfaham E; Debus J; Kirova Y; Herfarth K; Eich HT
Cancers (Basel); 2020 Mar; 12(3):. PubMed ID: 32183106
[No Abstract] [Full Text] [Related]
20. Exploration of modified progression-free survival as a novel surrogate endpoint for overall survival in immuno-oncology trials.
Wang ZX; Wu HX; Xie L; Lin WH; Liang F; Li J; Yang ZM; Xu RH
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33795385
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
